Reuters logo
BRIEF-BeiGene presents updated data from Phase 1 study of BTK inhibitor BGB-3111
2017年6月15日 / 下午2点26分 / 3 个月前

BRIEF-BeiGene presents updated data from Phase 1 study of BTK inhibitor BGB-3111

June 15 (Reuters) - BeiGene Ltd:

* Presented updated data from ongoing Phase 1 study of Bruton’s tyrosine kinase inhibitor BGB-3111 in patients with Waldenström’s macroglobulinemia

* VGPR rate also further supports continued evaluation of BGB-3111 in its global, head-to-head Phase 3 study against ibrutinib in WM

* Says updated Phase 1 data continue to demonstrate that BGB-3111 is well tolerated Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below